These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9190996)

  • 21. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
    Brown RW; Clark GM; Tandon AK; Allred DC
    Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology.
    Malle D; Valeri RM; Photiou C; Kaplanis K; Andreadis C; Tsavdaridis D; Destouni C
    Acta Cytol; 2005; 49(1):11-6. PubMed ID: 15717748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.
    Thirkettle I; Harvey P; Hasleton PS; Ball RY; Warn RM
    Histopathology; 2000 Jun; 36(6):522-8. PubMed ID: 10849094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas.
    Gaffey MJ; Mills SE; Swanson PE; Zarbo RJ; Shah AR; Wick MR
    Am J Surg Pathol; 1992 Jun; 16(6):593-9. PubMed ID: 1599037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
    Morgan RL; De Young BR; McGaughy VR; Niemann TH
    Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
    Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
    Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
    Bejui-Thivolet F; Patricot LM; Vauzelle JL; Viac J
    Pathol Res Pract; 1984 Sep; 179(1):67-73. PubMed ID: 6209691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. E-cadherin in mesothelioma.
    Jeffers M
    Hum Pathol; 1996 Nov; 27(11):1245-6. PubMed ID: 8912839
    [No Abstract]   [Full Text] [Related]  

  • 38. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.
    Hammar SP; Bockus DE; Remington FL; Rohrbach KA
    Ultrastruct Pathol; 1996; 20(4):293-325. PubMed ID: 8837337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.